Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction

Boińska, Joanna; Koziński, Marek; Kasprzak, Michał; Ziółkowska, Katarzyna; Dziembowska, Inga; Ziółkowski, M.; Kubica, Jacek; Rość, Danuta

doi:10.1080/09537104.2019.1693037

Cited by 5 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many overlapping circadian rhythms, including heart rate, catecholamine levels, rest–activity exertion, posture, as well as emotional stress (i.e., cortisol levels), seem to be involved in the pathogenesis of acute myocardial infarction (AMI) in the morning hours [ 1 , 2 ]. Significant changes in fibrinolytic parameters have been proposed as other potential triggers of AMI [ 3 , 4 , 5 ]. Up-to-date studies indicate that any disturbances in the fibrinolytic system may contribute to the development of a serious hypercoagulable state.…”

Section: Introductionmentioning

confidence: 99%

Diurnal Oscillations of Fibrinolytic Parameters in Patients with Acute Myocardial Infarction and Their Relation to Platelet Reactivity: Preliminary Insights

Boińska

Koziński

Kasprzak

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

There is limited information about diurnal changes in fibrinolysis parameters after acute myocardial infarction (AMI) and their relationship with on-treatment platelet reactivity. The aim of this study was to assess tissue plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-1), α2-antiplasmin (α2-AP) activity, and plasmin–antiplasmin (PAP) complexes in 30 AMI patients taking dual antiplatelet therapy (DAPT), i.e., acetylsalicylic acid and clopidogrel. Fibrinolytic parameters were assessed at four time points (6 a.m., 10 a.m., 2 p.m., and 7 p.m.) on the third day after AMI using immunoenzymatic methods. Moreover, platelet reactivity was measured using multiple-electrode aggregometry, to assess potential differences in fibrinolytic parameters in low/high on-aspirin platelet reactivity and low/high on-clopidogrel platelet reactivity subgroups of patients. We detected significant diurnal oscillations in t-PA and PAI-1 levels in the whole study group. However, PAP complexes and α2-AP activity were similar at the analyzed time points. Our study reveals a potential impact of DAPT on the time course of fibrinolytic parameters, especially regarding clopidogrel. We suggest the presence of diurnal variations in t-PA and PAI-1 concentrations in AMI patients, with the highest levels midmorning, regardless of platelet reactivity. Significantly elevated levels of PAI-1 during the evening hours in clopidogrel-resistant patients may increase the risk of thrombosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Diurnal Oscillations of Fibrinolytic Parameters in Patients with Acute Myocardial Infarction and Their Relation to Platelet Reactivity: Preliminary Insights

Boińska

Koziński

Kasprzak

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Rehabilitation exercises will not cause complications due to increased physical activity, and instead they prevent the multiple complications that can be caused by prolonged bed rest. The 7-day gradual early functional exercise program is based on the characteristics of sports metabolism in the young and middle-aged population, and includes specially devised scientific rehabilitation exercises to improve the body's anti-thrombotic ability, accelerate vascular remodeling, and reduce the incidence of postoperative angina, arrhythmia, and other complications (23,24).…”

Section: Discussionmentioning

confidence: 99%

Observation of the effect of a 7-day gradual early functional exercise program in middle-aged and young patients with acute myocardial infarction after percutaneous coronary intervention

Yang¹,

Sun²,

Feng³

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Acute myocardial infarction (AMI) is characterized by a critical condition, rapid progression, and a high fatality rate. Percutaneous coronary intervention (PCI) is the treatment of choice for AMI. The purpose of this study was to investigate the efficacy of a 7-day gradual early functional exercise program after PCI in young and middle-aged patients with AMI.Methods: A total of 106 young and middle-aged patients with AMI at the Affiliated Hospital of Jiangnan University from May 2018 to May 2019 were selected and divided into 2 groups according to the random number table method (n=53 per group). Both groups were treated with PCI, and the control group then received routine functional exercises after surgery, whilst the observation group received a 7-day gradual early functional exercise program after surgery. Functional exercise compliance, daily life ability before and after intervention, changes in quality of life, and postoperative complications after 1 year were compared between the 2 groups. Results:The functional exercise compliance of the observation group was significantly higher than that of the control group (P<0.05). The daily living ability of the observation group was also significantly better than that of the control group after the intervention (P<0.05). The physical activity, emotional response, diet, adverse drug reactions, and anxiety medication scores of the observation group after the intervention were lower than those of the control group (P<0.05). Furthermore, the postoperative complications and total complication rate after 1 year in the observation group was lower than the control group (P<0.05). Conclusions:The application of a 7-day gradual early functional exercise program in young and middleaged patients with AMI after PCI can improve functional exercise compliance, daily life ability, quality of life, and reduce the incidence of complications.

show abstract

“…Tolerability of DAPT during the recommended 12-month therapy period and reduction of the risk of ischemic events outweighing the elevated bleeding risk is a premise for prolonged therapy with a P2Y12 receptor inhibitor and ASA [23][24][25]. According to the citations in the ESC guidelines [10,11], indications to use clopidogrel, prasugrel, or ticagrelor in combination with ASA in patients with CCS after ACS are based on the data coming from the DAPT [14,15,26], TL-PAS [16], and PEGASUS-TIMI 54 trials [17][18][19][20][21].…”

Section: Dual Antiplatelet Therapy With Asa and A P2y12 Receptor Inhibitormentioning

confidence: 99%

Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines

et al. 2020

Self Cite

View full text Add to dashboard Cite

The increased risk of non-cardiovascular death in patients receiving clopidogrel or prasugrel in comparison with the placebo group in the Dual Antiplatelet Therapy (DAPT) trial in contrast to the decreased risk of cardiovascular death and all-cause death seen in patients treated with low-dose ticagrelor in the EU label population of the PEGASUS-TIMI 54 trial, resulted in inclusion in the 2020 ESC NSTE-ACS guidelines the recommendation for use of clopidogrel or prasugrel only if the patient is not eligible for treatment with ticagrelor. The prevalence of the primary outcome composed of cardiovascular death, stroke, or myocardial infarction was lower in the low-dose rivaroxaban and acetylsalicylic acid (ASA) group than in the ASA-alone group in the COMPASS trial. Moreover, all-cause mortality and cardiovascular mortality rates were lower in the rivaroxaban-plus-ASA group. Comparison of the PEGASUS-TIMI 54 and COMPASS trial patient characteristics clearly shows that each of these treatment strategies should be addressed at different groups of patients. A greater benefit in post-acute coronary syndrome (ACS) patients with a high risk of ischemic events and without high bleeding risk may be expected with ASA and ticagrelor 60 mg b.i.d. when the therapy is continued without interruption or with short interruption only after ACS. On the other hand, ASA and rivaroxaban 2.5 mg b.i.d. seems to be a better option when indications for dual antithrombotic therapy (DATT) appear after a longer time from ACS (more than 2 years) and/or from cessation of DAPT (more than 1 year) and in patients with multiple vascular bed atherosclerosis. Thus, both options of DATTs complement each other rather than compete, as can be presumed from the recommendations. However, a direct comparison between these strategies should be tested in future clinical trials.

show abstract

Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction

Cited by 5 publications

References 32 publications

Diurnal Oscillations of Fibrinolytic Parameters in Patients with Acute Myocardial Infarction and Their Relation to Platelet Reactivity: Preliminary Insights

Diurnal Oscillations of Fibrinolytic Parameters in Patients with Acute Myocardial Infarction and Their Relation to Platelet Reactivity: Preliminary Insights

Observation of the effect of a 7-day gradual early functional exercise program in middle-aged and young patients with acute myocardial infarction after percutaneous coronary intervention

Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines

Contact Info

Product

Resources

About